



Adalimumab Timeline




Adalimumab Challenged Claim Types in IPR and Litigation*




*In *AbbVie v. Amgen* (1:16-cv-00666) and *AbbVie v. Boehringer Ingelheim* (1:17-cv-01065) AbbVie alleges that Defendants will infringe at least these claim types.

Adalimumab IPR Status




*Considering IPR2017-00826 and IPR2017-01008 as one IPR, and IPR2017-00827 and IPR2017-01009 as one IPR.

Adalimumab Method of Treatment Claim IPR Status



Adalimumab Formulation Claim IPR Status



*Considering IPR2017-00826 and IPR2017-01008 as one IPR, and IPR2017-00827 and IPR2017-01009 as one IPR.

FWD = Final Written Decision

Technology: Adalimumab is a human monoclonal antibody that inhibits tumor necrosis factor alpha (TNF α). TNF α is a cytokine cell signaling protein that is involved in the inflammatory response that occurs in autoimmune diseases.

	<i>AbbVie v. Amgen</i> 1:16-cv-00666 (D. Del.) Dismissed (Settled)	<i>AbbVie v. Boehringer Ingelheim</i> 1:17-cv-01065 (D. Del.)	<i>Amgen v. AbbVie</i> IPR2015-01514 Institution denied	<i>Amgen v. AbbVie</i> IPR2015-01517 Institution denied
8,663,945	x			
8,911,964	x			
8,916,157	x		x	
8,916,158				x
8,926,975		x		
8,961,973	x			
8,986,693	x			
9,018,361		x		
9,090,867		x		
9,096,666	x	x		
9,220,781	x			
9,255,143		x		
9,266,949		x		
9,272,041	x	x		
9,359,434	x			
9,365,645	x			
9,546,212		x		
	<i>Coherus v. AbbVie</i> IPR2016-00172 FWD: All claims unpatentable; Appeal pending	<i>Boehringer Ingelheim v. AbbVie</i> IPR2016-00408, IPR2016-00409 FWD: All claims unpatentable; Appeals pending	<i>Coherus v. AbbVie</i> IPR2016-00188 FWD: All claims unpatentable; Appeal pending	<i>Coherus v. AbbVie</i> IPR2016-00189 FWD: All claims unpatentable; Appeal pending
8,889,135	x	x		
9,017,680			x	
9,073,987				x

	<i>Coherus v. AbbVie</i> IPR2017-00822, IPR2017-00823 Institution denied	<i>Coherus v. AbbVie</i> IPR2017-00826 / IPR2017-01008 Institution denied	<i>Coherus v. AbbVie</i> IPR2017-00827 / IPR2017-01009 Institution denied
9,085,619	x	x	x
	<i>Sandoz v. AbbVie</i> IPR2017-01823 Institution denied	<i>Sandoz v. AbbVie</i> IPR2017-01987 Institution denied	<i>Sandoz v. AbbVie</i> IPR2017-01988 Institution denied
8,802,100	x		
8,911,737		x	
8,974,790			x
	<i>Sandoz v. AbbVie</i> IPR2017-02106 Instituted; pending	<i>Sandoz v. AbbVie</i> IPR2017-02105 Instituted; pending	<i>Coherus v. AbbVie</i> IPR2016-01018 Institution denied
9,067,992	x		
9,090,689		x	
9,114,166			x
	<i>Sandoz v. AbbVie</i> IPR2017-01824 Institution denied; Request for rehearing denied; Appeal No. 18-2142 pending	<i>Sandoz v. AbbVie</i> IPR2018-00002 Institution denied;; Appeal No. 18-2143 pending	
9,512,216	x		x
	<i>Sandoz v. AbbVie</i> IPR2018-00156 Institution denied	<i>AbbVie v. Sandoz</i> 3:18-cv-12668 (D.N.J.) Ongoing	
9,187,559	x		x
9,750,808			x

FWD = Final Written Decision